Guidant, Medtronic bristle at ICDs (implantable cardioverter defibrillators) delay in US
This article was originally published in Clinica
US ICD companies have denounced Medicare's plans to postpone a national coverage decision on the prophylactic use of implantable cardioverter defibrillators (ICDs) pending examination of data from the as-yet unpublished SCD-HeFT trial, sponsored by the National Heart Lung and Blood Institute.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.